Scancell (LON:SCLP) Hits New 52-Week High – What’s Next?

Scancell Holdings plc (LON:SCLP)’s share price hit a new 52-week high during trading on Wednesday . The company traded as high as GBX 14 and last traded at GBX 13.50, with a volume of 3979924 shares trading hands. The stock had previously closed at GBX 12.50.

Scancell Stock Performance

The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The company has a market cap of £140.10 million, a P/E ratio of -24.55 and a beta of 0.33. The business has a fifty day moving average of GBX 12.49 and a 200 day moving average of GBX 11.16.

Scancell (LON:SCLP) last announced its earnings results on Thursday, January 29th. The company reported GBX (0.55) EPS for the quarter. Scancell had a negative net margin of 116.98% and a positive return on equity of 90.29%. On average, equities analysts predict that Scancell Holdings plc will post -2.5361112 EPS for the current year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.